학술논문
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Document Type
article
Author
Maria Stefania Infante; Jon Salmanton-García; Ana Fernández-Cruz; Francesco Marchesi; Ozren Jaksic; Barbora Weinbergerová; Caroline Besson; Rafael F. Duarte; Federico Itri; Toni Valković; Tomáš Szotkovski; Alessandro Busca; Anna Guidetti; Andreas Glenthøj; Graham P. Collins; Valentina Bonuomo; Uluhan Sili; Guldane Cengiz Seval; Marina Machado; Raul Cordoba; Ola Blennow; Ghaith Abu-Zeinah; Sylvain Lamure; Austin Kulasekararaj; Iker Falces-Romero; Chiara Cattaneo; Jaap Van Doesum; Klára Piukovics; Ali S. Omrani; Gabriele Magliano; Marie-Pierre Ledoux; Cristina de Ramon; Alba Cabirta; Luisa Verga; Alberto López-García; Maria Gomes Da Silva; Zlate Stojanoski; Stef Meers; Tobias Lahmer; Sonia Martín-Pérez; Julio Dávila-Vals; Jens Van Praet; Michail Samarkos; Yavuz M. Bilgin; Linda Katharina Karlsson; Josip Batinić; Anna Nordlander; Martin Schönlein; Martin Hoenigl; Zdeněk Ráčil; Miloš Mladenović; Michaela Hanakova; Giovanni Paolo Maria Zambrotta; Nick De Jonge; Tatjana Adžić-Vukičević; Raquel Nunes-Rodrigues; Lucia Prezioso; Milan Navrátil; Monia Marchetti; Annarosa Cuccaro; Maria Calbacho; Antonio Giordano; Oliver A. Cornely; José-Ángel Hernández-Rivas; Livio Pagano
Source
Frontiers in Oncology, Vol 12 (2022)
Subject
Language
English
ISSN
2234-943X
Abstract
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p